Caldwell & Orkin’s iShares Biotechnology ETF IBB Stock Holding History

Caldwell & Orkin’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-7,800	Closed	-$763K	–	73
2017 Q1	$763K	Buy	+7,800	New	+$747K	0.43%	70

Other funds holding IBB

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Churchill Management Los Angeles, California $9.21B AUM 19.91% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Caldwell & Orkin's IBB Position: Q2 2017 in Review

Caldwell & Orkin sold out of iShares Biotechnology ETF (IBB) in Q2 2017, closing a stake of 7,800 shares — an estimated $763K sold.

Caldwell & Orkin first reported a position in IBB in Q1 2017 and held it in 1 quarter. The position peaked at $763K in Q1 2017. 561 funds tracked by Wall St. Rank hold IBB as of Q2 2017.

Caldwell & Orkin reported no remaining iShares Biotechnology ETF position as of Q2 2017 after selling out during the quarter.
Caldwell & Orkin sold 7,800 iShares Biotechnology ETF shares in Q2 2017, an estimated $763K.
Caldwell & Orkin first reported a position in iShares Biotechnology ETF in Q1 2017 and held it in 1 quarter.
Caldwell & Orkin's iShares Biotechnology ETF position peaked at $763K in Q1 2017.
561 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2017.

Based on Caldwell & Orkin's 13F filing for Q2 2017, filed 10 Aug 2017.